Skip to content

Enzastaurin prevents BBB Dysfunction in Mouse Multiple Sclerosis Model through Inhibition of Protein Kinase C

October 5, 2013

Enzastaurin, otherwise known as LY-317615, a known protein kinase C (PKC) inhibitor, is being developed as an anti-cancer agent by Eli Lilly.  German investigators presented an abstract on the effect of enzastaurin on the mouse blood brain barrier with results presented on October 4, 2013 at the Congress of the European Committee for the Treatment and Research in Multiple Sclerosis in Copenhagen, Denmark.  They showed that stabilization of the BBB by enzastaurin prevented T-cell migration thereby mitigating neuroinflammation in the mouse autoimmune encephalomyelitis model for multiple sclerosis.  The authors conclude that endothelial PKC is involved in BBB homeostasis and may provide a target for novel therapeutic inhibitors in the treatment of multiple sclerosis. 

A link to the abstract is found here:

From → Posts

Leave a Comment

Leave a Reply

%d bloggers like this: